Scleroderma gene expression and pathway signatures

Current Rheumatology Reports

Volumn 10, Issue 3, 2008, Pages 205-211

  Sargent, Jennifer L ^b   Milano, Ausra ^b   Connolly, M Kari ^b   Whitfield, Michael L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; PARKIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; STAT PROTEIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER;

BLOOD CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG LAVAGE; PATHOGENESIS; REVIEW; SCLERODERMA; SKIN BIOPSY; SKIN FIBROSIS; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 51449114924     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0034-5     Document Type: Review

References (44)

1. Glas AM, Floore A, Delahaye LJ, et al.: Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006, 7:278.
2. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature (London) 2000, 406:747-752.
3. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
4. Garber ME, Troyanskaya OG, Schluens K, et al.: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001, 98:13784-13789.
5. Troester MA, Hoadley KA, Sorlie T, et al.: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004, 64:4218-4226.
6. Whitfield ML, Finlay DR, Murray JI, et al.: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003, 100:12319-12324.
7. Gardner H, Shearstone JR, Bandaru R, et al.: Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006, 54:1961-1973.
8. Zhou X, Tan FK, Xiong M, et al.: Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005, 52:3305-3314.
9. Leask A: Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med 2004, 53:74-77.
10. Leask A, Abraham DJ, Finlay DR, et al.: Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002, 46:1857-1865.
11. Zhou X, Tan FK, Xiong M, et al.: Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001, 167:7126-7133.
12. Luzina IG, Atamas SP, Wise R, et al.: Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003, 48:2262-2274.
13. Luzina IG, Atamas SP, Wise R, et al.: Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002, 26:549-557.
14. Tan FK, Zhou X, Mayes MD, et al.: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006, 45:694-702.
15. Steen VD, Medsger Jr TA: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001, 44:2828-2835.
16. Valdes JJ, Barton AJ: Computational intelligence techniques: a study of scleroderma skin disease. Proceedings of The Genetic and Evolutionary Computation Conference (GECCO) 2007. Ottawa, ON: National Research Council Canada; 2007:2580-2587.
17. Renzoni EA, Abraham DJ, Howat S, et al.: Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res 2004, 5:24.
18. Fan C, Oh DS, Wessels L, et al.: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
19. Steen VD, Conte C, Owens GR, Medsger Jr TA: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283-1289.
20. Rottoli P, Magi B, Perari MG, et al.: Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005, 5:1423-1430.
21. Broekelmann TJ, Limper AH, Colby TV, McDonald JA: Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991, 88:6642-6646.
22. Corrin B, Butcher D, McAnulty BJ, et al.: Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994, 24:145-150.
23. Silver RM, Miller KS, Kinsella MB, et al.: Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990, 88:470-476.
24. Yurovsky VV, Wigley FM, Wise RA, White B: Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 1996, 48:84-97.
25. White B, Moore WC, Wigley FM, et al.: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
26. Ragno S, Romano M, Howell S, et al.: Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach. Immunology 2001, 104:99-108.
27. Kodelja V, Muller C, Politz O, et al.: Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998, 160:1411-1418.
28. Hieshima K, Imai T, Baba M, et al.: A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/ LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 1997, 159:1140-1149.
29. Bott CM, Doshi JB, Morimoto C, et al.: Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. Int Immunol 1993, 5:783-792.
30. Morel Y, Schiano de Colella JM, Harrop J, et al.: Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000, 165:4397-4404.
31. Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, et al.: Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000, 95:231-240.
32. Robertson G, Hirst M, Bainbridge M, et al.: Genomewide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 2007, 4:651-657.
33. Baechler EC, Batliwalla FM, Karypis G, et al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615.
34. Maas K, Chan S, Parker J, et al.: Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002, 169:5-9.
35. Mandel M, Gurevich M, Pauzner R, et al.: Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004, 138:164-170.
36. Mootha VK, Lindgren CM, Eriksson KF, et al.: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
37. Subramanian A, Tamayo P, Mootha VK, et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
38. Segal E, Shapira M, Regev A, et al.: Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet 2003, 34:166-176.
39. Liu ET: Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. Proc Natl Acad Sci U S A 2005, 102:3531-3532.
40. Whitfield ML, Sherlock G, Saldanha AJ, et al.: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002, 13:1977-2000.
41. Whitfield ML, George LK, Grant GD, Perou CM: Common markers of proliferation. Nat Rev Cancer 2006, 6:99-106.
42. Chang HY, Sneddon JB, Alizadeh AA, et al.: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7.
43. Chang HY, Nuyten DS, Sneddon JB, et al.: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005, 102:3738-3743.
44. Pannu J, Gardner H, Shearstone JR, et al.: Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum 2006, 54:3011-3021.